References
Chan OT, Madaio MP, Shlomchik MJ (1999) B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity. J Immunol 163(7):3592–3596
Edelbauer M, Jungraithmayr T, Zimmerhackl LB (2005) Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol 20(6):811–813
Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA (2005) B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44(12):1542–1545
Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52(10):3168–3174
Sfikakis PP, Boletis JN, Tsokos GC (2005) Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 17(5):550–557
Thatayatikom A, White AJ (2006) Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5(1):18–24
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jansson, A.F., Wintergerst, U., Renner, E.D. et al. Rituximab-induced long-term remission in two children with SLE. Eur J Pediatr 166, 177–181 (2007). https://doi.org/10.1007/s00431-006-0217-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-006-0217-x